To stop or not to stop an asthma biologic, that is the question
Date
2024-09
Authors
Philipenko, Brianne S.
Davis, Beth
Cockcroft, Donald W.
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
ORCID
Type
Article
Degree Level
Abstract
During a time when anti-asthma biologics are readily accessible, the article by Brightling et al1 in the current issue provides additional much needed evidence to discuss with patients with severe asthma when the inevitable question arises of “How long do I need to continue on my asthma biologic therapy?” With now 6 biologics available, including most recently tezepelumab that can be prescribed without biomarker restrictions, it has become increasingly easy to prescribe these medications. After achieving good asthma control, physicians are left to contemplate the question of “now what?” Are these medications lifelong therapies?
Description
Accepted manuscript
CC BY-NC-ND
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en
Keywords
asthma control, biologic therapy, tezepelumab
Citation
Philipenko, B. S., Davis, B., & Cockcroft, D. W. (2024). To stop or not to stop an asthma biologic, that is the question. Annals of Allergy, Asthma & Immunology, 133(3), 236–237. https://doi.org/10.1016/j.anai.2024.06.012
Degree
Department
Program
Advisor
Committee
Part Of
item.page.relation.ispartofseries
DOI
10.1016/j.anai.2024.06.012